About Inflazome
Inflazome is a Healthcare company based in Dublin (Ireland) founded in 2016, and was acquired by Roche in September 2020. Inhibitors of the inflammasome are developed for chronic inflammatory diseases. Inflazome has raised $62.67 million across 3 funding rounds from investors including Roche, The Michael J. Fox Foundation and Forbion. The company has 2 employees. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Diversified. Its legal entity is Inflazome Uk Limited.
Company details
Inflazome was founded in 2016 and is headquartered in Dublin, Ireland. In the biotechnology sector, small-molecule inhibitors targeting the inflammasome are developed to address chronic inflammatory diseases. These inhibitors block signals that trigger immune responses, potentially aiding treatments for conditions such as Parkinsons disease, Alzheimers disease, atherosclerosis, and type II diabetes. Operations focus on eliminating root causes of inflammation through this mechanism.
- Headquarters Dublin, Ireland
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website inflazome.com
- Social LinkedIn X
- Acquired by Roche (Sep 2020)
- Legal Name Inflazome Uk Limited
Funding Insights of Inflazome
Inflazome has successfully raised a total of $62.67M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1 million completed in March 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.67M
- Total Rounds 3
- Last Round Grant — $1M
- First Round $17M
(Sep 2016)
- Investors Count 5
All 3 funding rounds of Inflazome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2019 | $1M | Grant | – | – | |
| Nov 2018 | $45.67M | Series B | – | Forbion | |
| Sep 2016 | $17M | Series A | – | Novartis Venture Fund, Fountain Healthcare Partners | – |
6 investors in total: 6 institutional.
Investors in Inflazome
Inflazome has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, The Michael J. Fox Foundation and Forbion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Risk capital is provided to life sciences entrepreneurs. | fh-partners.com | Dublin, Ireland | ||
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Inflazome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inflazome
2 people are tracked at Inflazome (2 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Jeremy Skillington | Vice President, Business Development | Leadership |
Luke O'Neill | Co-founder & Chief Scientific Officer | Leadership |
Complete people profiles for Inflazome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Inflazome
4 dated milestones of Inflazome across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Inflazome is founded.
- Funding First funding round of $17.0M.
- Funding Latest funding round, Grant, of $1.0M.
- Exit Acquired by Roche.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inflazome
Complete news archive for Inflazome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inflazome
Inflazome was founded in 2016.
Inflazome is headquartered in Dublin, Ireland.
Inflazome is a funded company, having raised a total of $62.67M across 3 funding rounds to date. The company's 1st funding round was a Series A of $17M, raised on Sep 2016.
Inflazome has 2 employees.
Inflazome was founded in 2016 and is headquartered in Dublin, Ireland. In the biotechnology sector, small-molecule inhibitors targeting the inflammasome are developed to address chronic inflammatory diseases. These inhibitors block signals that trigger immune responses, potentially aiding treatments for conditions such as Parkinsons disease, Alzheimers disease, atherosclerosis, and type II diabetes. Operations focus on eliminating root causes of inflammation through this mechanism.
Inflazome has 6 investors. Key investors include Roche, The Michael J. Fox Foundation, Forbion, Longitude Capital, and Novartis Venture Fund.
Inflazome operates through Inflazome Uk Limited.
Yes. Inflazome was acquired by Roche in September 2020.